ID
14355
Description
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01404949
Link
https://clinicaltrials.gov/show/NCT01404949
Keywords
Versions (1)
- 4/12/16 4/12/16 -
Uploaded on
April 12, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Acute Promyelocytic Leukemia NCT01404949
Eligibility Acute Promyelocytic Leukemia NCT01404949
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Previous treatment
Data type
boolean
Alias
- UMLS CUI [1]
- C0420262
Description
Communicable Diseases
Data type
boolean
Alias
- UMLS CUI [1]
- C0009450
Description
Pregnant Women
Data type
boolean
Alias
- UMLS CUI [1]
- C0033011
Description
Malignant Neoplasms
Data type
boolean
Alias
- UMLS CUI [1]
- C0006826
Description
Heart Diseases
Data type
boolean
Alias
- UMLS CUI [1]
- C0018799
Description
Life Threatening Adverse Event
Data type
boolean
Alias
- UMLS CUI [1]
- C1517874
Similar models
Eligibility Acute Promyelocytic Leukemia NCT01404949
- StudyEvent: Eligibility
C0206065 (UMLS CUI [2])